Innoplexus, a Germany- and India-based Data as a Service (DaaS) startup, has closed an undisclosed sum in pre-Series A funding from HCS, a Germany-based Venture VC firm.
With the capital, the startup plans to file more patent applications, further develop its trademark platform iPlexus, and invest in marketing.
Started in 2011, Innoplexus helps life sciences companies generate actionable insights across pre-clinical, clinical, regulatory and commercial stages of a drug. Its DaaS engine with real-time data and insights, along with an ecosystem of Continuous Analytics as a Service (CAaaS) applications, helps enterprises make better data-driven decisions.
Headquartered in Germany, with over 100 employees working from Pune, Innoplexus services large global pharma and life sciences companies. It helps companies move to continuous decision making by generating insights from structured and unstructured private and public data.
The company’s iPlexus platform helps life science firms to generate intelligence and insights across pre-clinical, clinical, regulatory and commercial stages of a drug across therapeutic areas and indications. It also helps researchers get quick, crisp and summarised snapshots of the current landscape in any given context through an intuitive semantic search, helping them make informed and data-backed decisions.
Dr. Gunjan Bhardwaj, Co-founder and CEO of Innoplexus, said, “We envision to fundamentally transform the DaaS landscape for life sciences by leveraging machine learning and artificial intelligence to generate insights from the public as well as enterprise data.”
Gaurav Tripathi, Co-founder and India CEO, said, “We are working in cutting-edge technology areas of Information Retrieval, Network Analysis, Computer Vision and Ontologies and are one of the rare startups with a strong focus on creating proprietary Intellectual Property.”
Pressemitteilung vom 08.01.2025 Die Amrit AG, ein Unternehmen der Partex Gruppe - einem führenden Anbieter von KI-Lösungen im Gesundheitswesen - gibt heute de...
Partnership aims to expand therapeutic potential of proprietary autotaxin inhibitor through AI-driven approach Frankfurt, Germany – Date – Partex, a leader in ...
Frankfurt, Germany, 3 rd June 2024, 9am CET Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to announce i...
Frankfurt, Germany, 23 April 2024 – Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to announce its partnership wi...
Frankfurt, Germany; 28 March 2024 – Partex Group, a pioneer in AI-driven drug discovery, announces a collaboration with Althea DRF Lifesciences, an established ...
During the German Cancer Congress 2024 in Berlin, the companies Innoplexus AG /Amrit AG, companies of Partex N.V., presented the results of a pilot project carr...
Frankfurt, Germany; 14 March 2024 Partex Group, a pioneer in AI-driven drug discovery, today announces a collaboration with global pharmaceutical giant Sanofi, ...
January 02, 2024 - Innoplexus and Amrit AG, members of the Partex NV Group, providers of innovative technology for health data analysis, and AIO Studien gGmbH, ...
Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience. Anavex Life Sciences Corp. and Partex NV ...
The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary medical exchange,...
Innoplexus wins Horizon Interactive Gold Award for Curia App
Read More